Clinical Trials Logo

Percutaneous Coronary Intervention clinical trials

View clinical trials related to Percutaneous Coronary Intervention.

Filter by:

NCT ID: NCT03656848 Not yet recruiting - Clinical trials for Coronary Artery Disease

The FAVOR III China Study

FAVORIII
Start date: October 1, 2018
Phase: N/A
Study type: Interventional

The overall purpose of the FAVOR III China trial is to investigate if a strategy of quantitative flow ratio (QFR)-guided percutaneous coronary intervention (PCI) yields superior clinical outcome and cost-effectiveness compared to a strategy of standard coronary angiography-guided PCI in evaluation of patients with coronary artery disease.

NCT ID: NCT03614559 Recruiting - Clinical trials for Percutaneous Coronary Intervention

Contemporary Clinical Treatment and Long-term Outcomes in Patient With Coronary Chronic Total Occlusion

PCI
Start date: May 6, 2018
Phase:
Study type: Observational

In order to know more about contemporary clinical treatment ,epidemiological characteristics, and long-term outcomes in patients with Coronary Chronic Total Occlusion(CTO)in China, the study through collecting and effective analyzing basic information, cardiovascular characteristics, contemporary clinical treatment , and long-term outcomes of CTO patients ,to describe the relevant risk factors ,the contemporary incidence of CTOs and the success rates of CTO percutaneous coronary intervention (PCI), as well as the complications and long-term outcomes of these patients, to explore the relevant factors which affecting the success rates of PCI therapy and to provide safer and more effective advice for the treatment of CTO.

NCT ID: NCT03613337 Recruiting - Clinical trials for Coronary Heart Disease

Effect of Smoking Status and Genetic Risk Factors on Restenosis and Efficacy of Clopidogrel After de Novo Percutaneous Coronary Intervention

Start date: May 1, 2018
Phase:
Study type: Observational

Restenosis occurs for many different reasons. Over the years, many predictive clinical, biological, genetic, epigenetic, lesion-related, and procedural risk factors for restenosis have been identified. Smoking is one of most important factors, however the results were contradictory. And the genetic factors of restenosis have been studied mostly in European populations. Based on literature review, study of candidate genes for restenosis in Chinese population was insufficient. With due attention to this matter mentioned above, the investigators aim to preliminary explore genetic variation and smoking effect on clinical restenosis in patients diagnosed with after percutaneous coronary intervention in the Chinese population, with correlation analysis of factors and gene-set analysis of biological pathways related to restenosis and platelet approach were widely used in this study.

NCT ID: NCT03611933 Completed - Clinical trials for Coronary Artery Disease

Effects of Position Change After PCI

Start date: July 2014
Phase: N/A
Study type: Interventional

Aims and objectives: To determine the effect of position change that is applied after percutaneous coronary intervention on vital signs, back pain, and vascular complications. Background: In order to minimize the post-procedure complications, patients are restricted to prolonged bed rest that is always accompanied by back pain and and hemodynamic instability. Design: Randomized-controlled quasi experimental study Methods: The study sample chosen for this study included 200 patients who visited a hospital in Turkey between July 2014 and November 2014. Patients were divided into two groups by randomization. Patients in the control group (CG, n = 100) were put in a supine position, in which the head of the bed (HOB) was elevated to 15°, the patient's leg on the side of the intervention was kept straight and immobile; positional change was applied to patients in the experimental group (EG, n = 100).

NCT ID: NCT03599284 Recruiting - Clinical trials for Coronary Artery Disease

The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel

Start date: August 30, 2018
Phase: Phase 2
Study type: Interventional

This is a multi-center, randomized, double-blind, triple-dummy, parallel-controled, dose-exploration phase II trial. Patients with coronary atherosclerotic heart disease and planned percutaneous coronary intervention (PCI) will be randomized after informed consent, in a 1:1:1:1 ratio to the following treatment groups: Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days; Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days; Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days; Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days. The primary purpose of this trial is to evaluate the efficacy, safety of vicagrel antiplatelet therapy and explore dose in patients with coronary atherosclerotic heart disease during and after PCI compared with clopidogrel.

NCT ID: NCT03562572 Active, not recruiting - Clinical trials for Coronary Artery Disease

FFR Driven Complete Revascularization Versus Usual Care in NSTEMI Patients and Multivessel Disease

SLIM
Start date: May 1, 2018
Phase: N/A
Study type: Interventional

To compare FFR guided complete revascularization during the index procedure with usual care in non-STEMI patients with multivessel disease.

NCT ID: NCT03557385 Not yet recruiting - Clinical trials for Percutaneous Coronary Intervention

Adenosine Contrast CorrELations in Evaluating RevAscularizaTION

ACCELERATION
Start date: July 2018
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare FFR measurements done with adenosine to FFR measurements done with contrast, where the contrast is injected using the ACIST CVi automated contrast injector. The ACCELERATION study will support a safer approach to FFR for patients by potentially reducing toxic drug exposure (adenosine). The 2 main objectives of the study are: 1. Perform a methods comparison between cFFR and the reference standard aFFR, where cFFR is performed using an automated injector with a standardized volume and rate of delivery of contrast with known osmolality. 2. Evaluate the association between final post-PCI FFR and long-term clinical outcomes. The long-term clinical outcomes will include TVR and composite MACE (death, MI, and TVR) at 30 days and 1 year.

NCT ID: NCT03522077 Recruiting - Clinical trials for Percutaneous Coronary Intervention

RAVE: Radial Artery Vascular Complication and Resource Utilization

Start date: May 9, 2018
Phase: Phase 4
Study type: Interventional

The primary objective of this open label study is to compare the rate of vascular complications associated with the use of the SoftSeal®-STF hemostatic pad in subjects undergoing transradial catherization when compared to the VascBand™ Hemostat. Patients will be randomized after radial access is achieved in 1:1 for each group.

NCT ID: NCT03476369 Recruiting - Clinical trials for Percutaneous Coronary Intervention

Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention

FACTPCI
Start date: April 18, 2018
Phase: Phase 4
Study type: Interventional

During a percutaneous coronary intervention (PCI), Fentanyl is commonly used for sedation. Ticagrelor is also routinely used as anti-platelet agent during PCI. However, a recent study has demonstrated the decrease in effectiveness of Ticagrelor when administered along with Fentanyl. Hence this study was designed to further assess the interaction between crushed vs non crushed Ticagrelor and Fentanyl given during PCI procedures.

NCT ID: NCT03474432 Not yet recruiting - Clinical trials for Percutaneous Coronary Intervention

SOLEMN Study - Synergy Optical Coherence Tomography in Left Main PCI

SOLEMN
Start date: April 15, 2018
Phase: N/A
Study type: Interventional

BACKGROUD: Percutaneous coronary intervention (PCI) is increasingly used to treat unprotected left main coronary artery stenosis. Protected LM PCI is considered standard of care in most centers. OCT allows for precise determination of stent placement, stent expansion and apposition. The pattern of vessel healing can be very precisely studied if immediate post-stent implantation OCT/IVUS data is compared to the 6-month post-PCI interval. While OCT cannot be optimally used for ostial lesion imaging, IVUS can be used to image ostial lesions/stent placement. Optimal and consistent vessel healing is particularly important in LM PCI where stent thrombosis is a potential complication with serious adverse outcome. HYPOTHESIS: Due to the absorption of the polymer of the Boston Scientific Synergy Stent over time, early strut coverage patterns and timeline may be different than previously observed in DES and BMS stents in LM PCI. Late acquired stent malapposition (LASM) is expected to differ from previous observations with traditional DES/BMS. Stent coverage in LM PCI will be studied with OCT or IVUS at six and 12 months and compared to OCT or IVUS at the time of stent implantation. OCT/IVUS data will be analyzed in a core lab (CRF) and correlated with clinical outcomes at 6 and 12 months.